Answers are grounded in this paper and cite their sources.
Shows slower cognitive decline and better test performance in Parkinson's disease patients taking statins, indicating possible protective cognitive effects.
BACKGROUND: The relationship between statins and cognition in Parkinson's disease (PD) is poorly understood. OBJECTIVES: Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. METHODS: Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. RESULTS: At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.
No takes yet. Share an insight, caveat, or question.
Deck et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: